Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660927 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL10186100 | 0.92 | NPC1 (0.46) | SMN1; SMN2ALDH1A1HRH3KMT2ANPC1 | |
| SCHEMBL10184946 | 0.92 | ALDH1A1 (0.49) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10185009 | 0.91 | KDM4E (0.51) | SMN1; SMN2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL10186387 | 0.90 | CHRM1 (0.45) | SMN1; SMN2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL10184940 | 0.89 | EPHX2 (0.48) | HRH3CHRM1DGAT1POLB | |
| SCHEMBL10185026 | 0.89 | HRH3 (0.44) | SMN1; SMN2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL10184280 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10184812 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1HRH3MEN1 | |
| SCHEMBL10184889 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | SMN1; SMN2 4464/4885KDM4E 3060/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.